Develops oncology therapies, focusing on targeted small molecule drugs and combination therapies for hematologic malignancies.
MEI Pharma, Inc. is an advanced-stage pharmaceutical company dedicated to the development and commercialization of cutting-edge therapies for cancer treatment. At the forefront of its pipeline is Zandelisib, an oral inhibitor of phosphatidylinositol 3-kinase delta currently undergoing Phase III clinical trials for relapsed/refractory follicular lymphoma. Additionally, Zandelisib is being evaluated in a Phase Ib multi-arm trial targeting various B-cell malignancies. The company also advances Voruciclib, an oral inhibitor of cyclin-dependent kinase 9, currently in Phase Ib trials for acute myeloid leukemia and B-cell malignancies.
MEI Pharma is actively developing ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex. This innovative therapy is in Phase I clinical trials for the treatment of human epidermal growth factor receptor 2 negative breast cancer. Furthermore, MEI Pharma is exploring Pracinostat, an oral histone deacetylase inhibitor, in Phase II clinical trials for patients with myelodysplastic syndrome. The company has established strategic partnerships, including a license, development, and commercialization agreement with Kyowa Kirin Company, a clinical collaboration with BeiGene, Ltd., and agreements with Helsinn Healthcare SA and Presage Biosciences, Inc.
Originally incorporated as Marshall Edwards, Inc., MEI Pharma rebranded in July 2012 to reflect its expanded focus and commitment to advancing oncology treatments. Headquartered in San Diego, California, MEI Pharma continues to drive innovation in cancer therapeutics, leveraging its robust pipeline and strategic partnerships to address critical unmet needs in cancer care worldwide.